These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 26547601)
1. HPV9: Combating HPV-associated cancers by strengthening serotype defenses. Dougherty SA; Hayney MS J Am Pharm Assoc (2003); 2015; 55(6):670-672. PubMed ID: 26547601 [No Abstract] [Full Text] [Related]
2. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial. Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002 [TBL] [Abstract][Full Text] [Related]
3. [Diseases caused by human papillomavirus -- the possibilities and the public health advantages of prevention]. Acs N; Bata Z; Danko D; Hernádi Z; Kálmán M; Kornya L; Kovács J; Mézáros G; Molnár MP; Mór Z; Novák Z; Sobel G; Szentirmay Z; Takács L; Tisza T Orv Hetil; 2012 Dec; 153 Suppl():3-38. PubMed ID: 23687666 [No Abstract] [Full Text] [Related]
9. Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa. Mugo N; Ansah NA; Marino D; Saah A; Garner EI Hum Vaccin Immunother; 2015; 11(6):1323-30. PubMed ID: 25912475 [TBL] [Abstract][Full Text] [Related]
17. A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US. Dunne EF; Datta SD; E Markowitz L Cancer; 2008 Nov; 113(10 Suppl):2995-3003. PubMed ID: 18980283 [TBL] [Abstract][Full Text] [Related]
18. Vaccination for the prevention of human papillomavirus cancers. CA Cancer J Clin; 2020 Jul; 70(4):281-282. PubMed ID: 32639021 [No Abstract] [Full Text] [Related]
19. Human papillomavirus vaccine and cervical cancer prevention: practice and policy implications for pharmacists. McIntosh J; Sturpe DA; Khanna N J Am Pharm Assoc (2003); 2008; 48(1):e1-13; quiz e14-7. PubMed ID: 18192123 [TBL] [Abstract][Full Text] [Related]
20. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]